Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
Provided By GlobeNewswire
Last update: Nov 7, 2024
- Improved safety and efficacy profiles for ADG126 versus ipilimumab driven by precision masking, novel epitope-dependent antibody-dependent cellular cytotoxicity (ADCC) and partial CTLA-4 blockade -
Read more at globenewswire.comNASDAQ:ADAG (3/7/2025, 8:03:31 PM)
2.03
-0.07 (-3.33%)
Find more stocks in the Stock Screener
